HCV's days are numbered: Next-generation direct-acting antivirals and host-targeting agents

Antiviral Therapy

Volumn 17, Issue 6 PART B, 2012, Pages 1133-1146

  Serrano, Beatriz Calle ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ASUNAPREVIR; BI 207127; BOCEPREVIR; DACLATASVIR; DANOPREVIR; ENZYME INHIBITOR; FALDAPREVIR; FILIBUVIR; LOMIBUVIR; MERICITABINE; MIRAVIRSEN; MK 5172; NONSTRUCTURAL PROTEIN 5B POLYMERASE INHIBITOR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON LAMBDA; PROTEINASE INHIBITOR; PSI 938; R 7218; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL RESISTANCE; BINDING AFFINITY; BINDING SITE; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERBILIRUBINEMIA; LIVER CIRRHOSIS; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN DEFECT; UNSPECIFIED SIDE EFFECT; VIRUS MORPHOLOGY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYCLOPHILINS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; MICRORNAS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL STRUCTURES; VIRUS REPLICATION;

EID: 84867266290     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2425     Document Type: Review

References (128)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52. Medline doi:10.1056/NEJM200107053450107
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562. Medline doi:10.1056/NEJM199908193410802
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127 Suppl 1: S35-S50. Medline doi:10.1053/j.gastro.2004.09.014
4. Brown RS. Hepatitis C and liver transplantation. Nature 2005; 436: 973-978. Medline doi:10.1038/nature04083
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. Medline doi:10.1016/S0140-6736(01)06102-5
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982. Medline doi:10.1056/NEJMoa020047
7. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206. Medline doi:10.1056/NEJMoa1010494
8. Jacobson I. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study. Hepatology 2010; 52 Suppl 1: 427A.
9. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024. Medline doi:10.1056/NEJMoa1014463
10. Ciesek S, Manns MP. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 69-71. Medline doi:10.1038/nrgastro.2010.219
11. Yu X, Qiao M, Atanasov I, et al. Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology 2007; 367: 126-134. Medline doi:10.1016/j.virol.2007.05.038
12. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796. Medline doi:10.1038/nm1268
13. Takahashi K, Kishimoto S, Yoshizawa H, Okamoto H, Yoshikawa A, Mishiro S. p26 protein and 33-nm particle associated with nucleocapsid of hepatitis C virus recovered from the circulation of infected hosts. Virology 1992; 191: 431-434. Medline doi:10.1016/0042-6822(92)90204-3
14. Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H (Editors). Hepatology. A clinical textbook. Düsseldorf: Flying Publisher 2009.
15. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107. Medline doi:10.1126/science.282.5386.103
16. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48: 1769-1778. Medline doi:10.1002/hep.22549
17. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009; 49: 1069-1082. Medline doi:10.1002/hep.22773
18. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009; 16: 75-90. Medline doi:10.1111/j.1365-2893.2008.01012.x
19. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593. Medline doi:10.1056/NEJMoa0808010
20. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103-112. Medline doi:10.1053/j.gastro. 2006.11.011
21. Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008; 47: 817-826. Medline doi:10.1002/hep.22131
22. Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. J Hepatol 2011; 55: 972-979. Medline doi:10.1016/j.jhep. 2011.01.046
23. Zeuzem S, Soriano V, Asselah T, et al. Virologic response to an interferon-free regimen of BI 201335 and BI 207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the SOUND-C2 study. Hepatology 2011; 54 Suppl 1: 1436A.
24. Failla C, Tomei L, De Francesco R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol 1994; 68: 3753-3760. Medline (Pubitemid 24177400)
25. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-1148. Medline doi:10.1126/science.1082604
26. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102: 2992-2997. Medline doi:10.1073/pnas.0408824102
27. Kim DW, Gwack Y, Han JH, Choe J. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem Biophys Res Commun 1995; 215: 160-166. Medline doi:10.1006/bbrc.1995.2447
28. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993; 67: 3835-3844. Medline (Pubitemid 23180705)
29. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 343-355. Medline doi:10.1016/S0092-8674(00)81351-3
30. Zhou Y, Müh U, Hanzelka BL, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007; 282: 22619-22628. Medline doi:10.1074/jbc.M610207200
31. Zhou Y, Bartels DJ, Hanzelka BL, et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2008; 52: 110-120. Medline doi:10.1128/AAC.00863-07
32. Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54: 1878-1887. Medline doi:10.1128/AAC.01452-09
33. Manns MP, Gane E, Rodriguez-Torres M, et al. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized Phase II study. Hepatology 2012; doi:10.1002/hep. 25743. Medline doi:10.1002/hep.25743
34. Kazmierski WM (Editor). Antiviral drugs: from basic discovery through clinical trials. 1st ed. Hoboken, NJ: John Wiley & Sons 2011.
35. Forestier N, Larrey D, Marcellin P, et al. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. J Infect Dis 2011; 204: 601-608. Medline doi:10.1093/infdis/jir315
36. Terrault NA. High sustained virologic response (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus pegIFN α-2a (40kd) and ribavirin (P/R) in treatment naive HCV genotype 1(G1) patients: results from the ATLAS study. Hepatology 2011; 54 Suppl 1: 398A.
37. Gane EJ, Roberts SK, Stedman CAM, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475. Medline doi:10.1016/S0140-6736(10)61384-0
38. Manns M, Reesink H, Berg T, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011; 16: 1021-1033. Medline doi:10.3851/IMP1894
39. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a Phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138: 913-921. Medline doi:10.1053/j.gastro.2009.10.033
40. Lin T, Devogerlare B, Lenz O, et al. Inhibitory activity of TMC435350 on HCV NS3/4A proteases from genotypes 1 to 6. Hepatology 2008; 48 Suppl 1: 1166A.
41. Lin T-I, Lenz O, Fanning G, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009; 53: 1377-1385. Medline doi:10.1128/AAC.01058-08
42. Fried MW, Buti M, Dore GJ, et al. TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients. Hepatology 2011; 54 Suppl 1: 1429A.
43. Medivir. TMC435-based therapy significantly improved viral cure rates in patients who failed prior treatment for hepatitis C. (Updated 2 November 2011. Accessed 28 August 2012.) Available from http://www.medivir.se/v4/en/ir-media/ pressrelease.cfm?year=2011&releaseid=614139
44. White PW, Llinàs-Brunet M, Amad M, et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 2010; 54: 4611-4618. Medline doi:10.1128/AAC.00787-10
45. Manns MP, Bourlière M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 1114-1122. Medline doi:10.1016/j.jhep.2010.08.040
46. Pol S, Berg T, Bonacini M, et al. Virological response and safety of BI 201335 protease inhibitor, peginterferon alfa 2a and ribavirin treatment of HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous peginterferon/ribavirin. Hepatology 2009; 50 Suppl 4: 228A.
47. Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141: 2047-2055. Medline doi:10.1053/j.gastro.2011.08.051
48. Petry AS. Safety and antiviral activity of MK-5172, a next generation HCV NS3/4a protease inhibitor with a broad HCV genotipic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 2011; 54 Suppl 1: 531A.
49. Carroll S, McCauley J, Ludmerer S, et al. 39 MK-5172: a novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants. J Hepatol 2010; 52 Suppl 1: S17. doi:10.1016/S0168-8278(10)60041-4
50. Graham D. MK-5172, a second generation HCV NS3/4a protease inhibitor is active against common resistance associated variants (RAVs) and exhibits gross-genotype activity. Hepatology 2011; 54 Suppl 1: 543A.
51. Caro L. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship for MK-5172, a novel hepatitis c virus (HCV) NS3/4a protease inhibitor, in genotype 1 and genotype 3 HCV-infected patients. Hepatology 2011; 54 Suppl 1: 1005A.
52. Schmitz U, Tan S-L. NS5A - from obscurity to new target for HCV therapy. Recent Pat Antiinfect Drug Discov 2008; 3: 77-92. Medline doi:10.2174/ 157489108784746597
53. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008; 4: e1000032. Medline doi:10.1371/journal.ppat.1000032
54. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85: 2485-2502. Medline doi:10.1099/vir.0.80204-0
55. Achillion. First-in-human trial to evaluate safety and tolerability of first generation NS5A inhibitor in both healthy subjects and genotype 1 HCV-infected patients. (Updated 11 July 2011. Accessed 28 August 2012.) Available from http://ir.achillion.com/releasedetail.cfm?ReleaseID=590298
56. Huang M, Yang G, Patel D, et al. 1212 ACH-2928: a novel highly potent HCV NS5A inhibitor with favorable preclinical characteristics. J Hepatol 2011; 54 Suppl 1: S479. doi:10.1016/S0168-8278(11)61214-2
57. Lemm JA, O'Boyle D, Liu M, et al. Identification of hepatitis C virus NS5A inhibitors. J Virol 2010; 84: 482-491. Medline doi:10.1128/JVI.01360-09
58. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100. Medline doi:10.1038/nature08960
59. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C Virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54: 3641-3650. Medline doi:10.1128/AAC.00556- 10
60. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224. Medline doi:10.1056/NEJMoa1104430
61. Dutartre H, Bussetta C, Boretto J, Canard B. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2′-modified nucleotide analogues. Antimicrob Agents Chemother 2006; 50: 4161-4169. Medline doi:10.1128/AAC.00433-06
62. Hewlett G, Hallenberger S, Rübsamen-Waigmann H. Antivirals against DNA viruses (hepatitis B and the herpes viruses). Curr Opin Pharmacol 2004; 4: 453-464. Medline doi:10.1016/j.coph.2004.06.004
63. Vivet-Boudou V, Didierjean J, Isel C, Marquet R. Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell Mol Life Sci 2006; 63: 163-186. Medline doi:10.1007/s00018-005-5367-x
64. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53: 1742-1751. Medline doi:10.1002/hep.24262
65. Legrand-Abravanel F, Nicot F, Izopet J. New NS5B polymerase inhibitors for hepatitis C. Expert Opin Investig Drugs 2010; 19: 963-975. Medline doi:10.1517/13543784.2010.500285
66. Ma H, Jiang W-R, Robledo N, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-d-2′-deoxy- 2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem 2007; 282: 29812-29820. Medline doi:10.1074/jbc.M705274200
67. Guedj J, Dahari H, Tafoya E, Smith P, Perelson AS. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 2012; 55: 1030-1037. Medline doi:10.1002/hep.24788
68. Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007; 46 Suppl 1: 862A.
69. Rodriguez-Torres M, Lalezari J, Gane E, et al. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with peg-IFN and ribavirin: subanalysis by race/ethnicity, weight, and HCV genotype. Hepatology 2008; 48: 1160A.
70. Gane E, Rodriguez-Torres M, Nelson DR, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg BID with PEG-IFN and ribavirin for 28 days. Hepatology 2008; 48: 1024A.
71. Le Pogam S, Seshaadri A, Ewing A, et al. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010; 202: 1510-1519. Medline doi:10.1086/656774
72. Le Pogam S, Jiang W-R, Leveque V, et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 2006; 351: 349-359. Medline doi:10.1016/j.virol.2006.03.045
73. Margeridon S, Le Pogam S, Liu TF, et al. No detection of variants bearing NS5B S282T mericitabine (MCB) resistance mutation in DAA treatment-naive HCV genotype 1 infected patients using ultra-deep pyrosequencing (UDPS). Hepatology 2011; 54 Suppl 1: 532A.
74. Jensen D, Wedemeyer H, Herring PF, et al. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV Gt1/4 patients treated with RG7128 plus pegIFN alfa-2a (40kD)/RBV: planned week 12 interim analysis from the propel study. Hepatology 2010; 52 Suppl 1: 360A.
75. Pockros P, Jensen D, Tsai N, et al. 1359 First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with pefinterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial. J Hepatol 2011; 54 Suppl 1: S538. doi:10.1016/S0168- 8278(11)61361-5
76. Gilead. Viral relapse seen post treatment with GS-7977 plus ribavirin. Awaiting data for treatment-naive genotype 1 patients. (Updated 17 February 2012. Accessed 28 August 2012.) Available from http://www.gilead.com/pr-1662331
77. Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010; 285: 34337-34347. Medline doi:10.1074/jbc.M110.161802
78. Rodriguez-Torres M, Lawitz E, Flach S, et al. Antiviral activity, pharmacokinetics, safety, and tolerability of PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following single and 3 day multiple ascending oral doses in healthy volunteers and patients with chronic HCV infection. Hepatology 2009; 50 Suppl 4: 228A.
79. Nelson DR, Lalezari J, Lawitz E, et al. 1372 Once daily PSI-7977 plus PEG-IFN/RBV in HCV GT1: 98% rapid virologic response, complete early virologic response: the Proton study. J Hepatol 2011; 54 Suppl 1: S544. doi:10.1016/S0168-8278(11)61374-3
80. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. 61 Once daily PSI-7977 plus pegIFN/RBV in a phase 2B trial: rapid virologic suppression in treatment-naive patients with HCV GT2/GT3. J Hepatol 2011; 54 Suppl 1: S28. doi:10.1016/S0168-8278(11)60063-9
81. Gane E, Stedman C, Hyland R, et al. Once-daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. Hepatology 2011; 54 Suppl 1: 377A.
82. Lawitz E, Rodriguez-Torres M, Denning J, et al. 1370 once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCVRNA
83. Welsch C, Zeuzem S. Will interferon-free regimens prevail? Gastroenterology 2012; 142: 1352-1355. Medline doi:10.1053/j.gastro.2011.12.062
84. Mori J, Hammond JL, Srinivasan S, Jagannatha S, van der Ryst E. 35 Genotypic characterisation of filibuvir (PF-00868554) resistance in patients receiving four weeks co-administration of filibuvir with pegIFN/RBV (12 week analysis). J Hepatol 2010; 52 Suppl 1: S15. doi:10.1016/S0168-8278(10)60037-2
85. Troke PJF, Lewis M, Simpson P, et al. Characterization of resistance to the non-nucleoside NS5B inhibitor filibuvir in hepatitis C infected patients. Antimicrob Agents Chemother 2011; 56: 1331-1341. Medline doi:10.1128/AAC.05611- 11
86. Rodriguez-Torres M, Lawitz E, Conway B, et al. 31 Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naive genotype 1 HCV-infected patients. J Hepatol 2010; 52 Suppl 1: S14. doi:10.1016/S0168-8278(10)60033-5
87. Chauret N, Chagnon-Labelle C, Diallo M, et al. 939 Preclinical pharmacokinetic and adme characterization of VCH-222, a novel NS5B polymerase inhibitor. J Hepatol 2009; 50 Suppl 1: S341-S342. doi:10.1016/S0168-8278(09) 60941-7
88. Cooper C, Larouche R, Bourgault B, Chauret N, Proulx L. 940 Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor VCH-222 following single doses administration in healthy volunteers and antiviral activity in HCV-infected individuals. J Hepatol 2009; 50 Suppl 1: S342. doi:10.1016/S0168-8278(09)60942-9
89. Di Bisceglie AM, Nelson DR, Gane E, et al. 1363 VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C: Zenith study interim results. J Hepatol 2011; 54 Suppl 1: S540. doi:10.1016/S0168-8278(11)61365-2
90. Galat A. Function-dependent clustering of orthologues and paralogues of cyclophilins. Proteins 2004; 56: 808-820. Medline doi:10.1002/prot.20156
91. Chatterji U, Lim P, Bobardt MD, et al. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol 2010; 53: 50-56. Medline doi:10.1016/j.jhep. 2010.01.041
92. Yang F, Robotham JM, Nelson HB, Irsigler A, Kenworthy R, Tang H. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 2008; 82: 5269-5278. Medline doi:10.1128/JVI.02614-07
93. Liu Z, Yang F, Robotham JM, Tang H. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol 2009; 83: 6554-6565. Medline doi:10.1128/JVI.02550-08
94. Liu Z, Robida JM, Chinnaswamy S, et al. Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A. Hepatology 2009; 50: 25-33. Medline doi:10.1002/hep.22987
95. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-1288. Medline doi:10.1053/jhep.2003.50449
96. Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313: 42-47. Medline doi:10.1016/j.bbrc.2003.11.080
97. Coelmont L, Hanoulle X, Chatterji U, et al. DEB025 (alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE 2010; 5: e13687. Medline doi:10.1371/journal.pone.0013687
98. Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009; 49: 1460-1468. Medline doi:10.1002/hep.22835
99. Fischer G, Gallay P, Hopkins S. Cyclophilin inhibitors for the treatment of HCV infection. Curr Opin Investig Drugs 2010; 11: 911-918. Medline
100. Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006; 43: 761-770. Medline doi:10.1002/hep.21102
101. Flisiak R, Pawlotsky JM, Crabbe R, et al. 4 Once daily alisporivir (DEB025) plus pegifnalfa2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naive patients. J Hepatol 2011; 54 Suppl 1: S2. doi:10.1016/S0168-8278(11)60006-8
102. Pawlotsky J, Flisiak R, Rasenack J, et al. Once daily alisporivir interferon (IFN)-free regimens achieve high rates of early HCV clearance in previously untreated patients with hcv genotype (G) 2 or 3. Hepatology 2011; 54 Suppl 1: 1433A.
103. Puyang X, Poulin DL, Mathy JE, et al. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob Agents Chemother 2010; 54: 1981-1987. Medline doi:10.1128/AAC.01236- 09
104. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297. Medline doi:10.1016/S0092-8674(04)00045-5
105. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113. Medline doi:10.4161/rna.1.2.1066
106. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 2005; 309: 1577-1581. Medline doi:10.1126/science.1113329
107. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201. Medline doi:10.1126/science.1178178
108. Janssen HLA, Reesink HW, Zeuzem S, et al. A randomized, double-blind, placebo (PLB) controlled safety and anti-viral proof of concept study of Miravirsen (MIR), an oligonucleotide targeting miR-122, in treatment naive patients with genotype 1 (Gt1) chronic HCV infection. Hepatology 2011; 54 Suppl 1: 1430A.
109. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′ UTR. Proc Natl Acad Sci U S A 2011; 108: 4991. Medline doi:10.1073/pnas.1016606108
110. Boehme KW, Compton T. Innate sensing of viruses by Toll-like receptors. J Virol 2004; 78: 7867-7873. Medline doi:10.1128/JVI.78.15.7867-7873.2004
111. Schetter C, Vollmer J. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9. Curr Opin Drug Discov Devel 2004; 7: 204-210. Medline (Pubitemid 44111952)
112. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436: 953-960. Medline doi:10.1038/nature04080
113. Bergmann JF, de Bruijne J, Hotho DM, et al. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther 2011; 34: 443-453. Medline doi:10.1111/j.1365-2036.2011.04745.x
114. Muir A, Ghalib R, Lawitz E, et al. 32 A Phase 1, multi-center, randomized, placebo-controlled, dose-escalation study of IMO-2125, a TLR9 agonist, in hepatitis C-nonresponders. J Hepatol 2010; 52 Suppl 1: S14. doi:10.1016/S0168-8278(10)60034-7
115. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000; 81: 2341-2364. Medline
116. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77. Medline doi:10.1038/ni875
117. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017. Medline doi:10.1371/journal.ppat.1000017
118. Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52: 822-832. Medline doi:10.1002/hep.23743
119. Zeuzem S, Arora S, Box T, et al. Pegylated interferon-lambda (PegIFN-λ) shows superior viral response with improved safety and tolerability versus PegIFN-α-2a in HCV patients (G1/2/3/4): EMERGE Phase IIb through week 12. J Hepatol 2011; 54 Suppl 1: S538-S539. doi:10.1016/S0168- 8278(11)61362-7
120. Rodriguez-Torres M, Hillson JL, Bacon BR, et al. Safety and efficacy of Pegylated interferon lambda (peg-lambda) compared to pegylated interferon-α-2a (peg-alfa) in HCV-infected patients (G1/2/3) with compensated cirrhosis: EMERGE phase IIb efficacy and safety results through week 12. Hepatology 2011; 54 Suppl 1: 994A.
121. Chayama K. Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responders. Hepatology 2011; 54 Suppl 1: 1428A.
122. Dusheiko G, Nelson D, Reddy KR. Ribavirin considerations in treatment optimization. Antivir Ther 2008; 13 Suppl 1: 23-30. Medline (Pubitemid 351542495)
123. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A 1993; 90: 10583-10587. Medline doi:10.1073/pnas.90.22.10583
124. Santolini E, Pacini L, Fipaldini C, Migliaccio G, Monica N. The NS2 protein of hepatitis C virus is a transmembrane polypeptide. J Virol 1995; 69: 7461-7471. Medline
125. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007; 81: 8374-8383. Medline doi:10.1128/JVI.00690-07
126. Jin L, Peterson DL. Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Arch Biochem Biophys 1995; 323: 47-53. Medline doi:10.1006/abbi.1995.0008
127. Wölk B, Sansonno D, Kräusslich HG, et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol 2000; 74: 2293-2304. Medline doi:10.1128/JVI.74.5.2293-2304.2000
128. Rai R, Deval J. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. Antiviral Res 2011; 90: 93-101. Medline doi:10.1016/j.antiviral.2011.01.009